Table 2. Clinical information of trials using intensive chemotherapy in this study.
| Study | Patients (NO.) | Type of Disease | Median age (range) | Regimen | Dosage | CR (%) | ED (%) | Myelo-suppression (%) |
|---|---|---|---|---|---|---|---|---|
| Cytarabine (range of dose) | ||||||||
| 100-200mg/m2/d×7d | ||||||||
| Sun[34] | 18 | AML (Elderly) | NR (61–82) | HA | HHT 1-2mg/d×14d | 38.89 | 22.2 | 100 |
| Sun[46] | 12 | AML (Elderly) | NR (64–72) | HA | HHT 3-4mg/d×7d | 58.33 | 16.7 | NR |
| Ye[28] | 25 | AML (Elderly) | 68 (60–77) | DA | DNR 40mg/d×3d | 44 | 16 | 76 |
| Guo[56] | 16 | AML | NR (45–76) | HA | HHT 1-2mg/d×14d | 18.75 | 43.7 | 100 |
| Sun[70] | 16 | MDS/t-AML (advanced) | NR (45–76) | HA | HHT 1-2mg/d×14d | 18.75 | 43.7 | 100 |
| Zhang[74] | 20 | MDS/t-AML | 45 (32–75) | HA | HHT 3-4mg/m2/d×7d | 50 | NR | NR |
| Zheng[47] | 16 | AML (ND) | NR (30–47) | HA/DA | HHT 3-4mg/m2/d×7d | 37.50 | 18.7 | 31.2 |
| DNR 45mg/m2/d×3d | ||||||||
| Tong[35] | 27 | AML (Elderly) | NR (60–76) | DA | DNR 40mg/m2/d×3d | 33.33 | 11.1 | NR |
| Liu[20] | 34 | AML (ND) | 62 (54–68) | HA | HHT 4mg/d×7d | 32.35 | 8.82 | 82.3 |
| Jia[63] | 15 | AML (R/R) | 36 (15–41) | DA | DNR 45mg/m2/d×4-5d | 46.67 | NR | NR |
| Yang[33] | 21 | AML (Elderly) | 68 (60–73) | DA/HA/MA | DNR 40mg/m2/d×3d | 33.33 | 28.5 | NR |
| HHT 3-4mg/d×5-7d | ||||||||
| MITX 5-10mg/m2/d×3d | ||||||||
| Su[68] | 33 | MDS/t-AML | 65 (47–85) | HA | HHT 2-3mg/d×7d | 33.33 | 0 | NR |
| Wu[48] | 21 | AML (R/R) | 44 (18–70) | MAE | MITX 10mg/m2/d×3d | 14.29 | NR | 66.6 |
| VP-16 60mg/m2/d×5d | ||||||||
| Deng[75] | 45 | MDS/t-AML (advanced) | 58 (38–76) | HA | HHT 1mg/m2/d×14d | 17.78 | NR | 73.3 |
| Zhou[53] | 18 | AML (Elderly) | 67 (60–81) | MA | MITX 4-6mg/m2/d×3d | 38.89 | 11.1 | NR |
| Zhang[54] | 22 | AML (Elderly) | NR (61–82) | HA | HHT 1mg/m2/d×14d | 36.36 | 0 | NR |
Abbreviations: CR = Complete response; ED = earlydeath; ND = newly diagnosed; R/R = relapsed/refractory; advanced = intermediate-2 or high risk; NR = not reported; HA = homoharringtonine (HHT) and cytarabine; DA = daunorubicin (DNR) and cytarabine; MA = mitoxantrone(MITX) and cytarabine; MAE = mitoxantrone (MITX), cytarabine and etoposide (VP-16).